The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review
Open accessAbstract
INTRODUCTION: Approximately a third of the population worldwide is chronically infected with Toxoplasma gondii. Pyrimethamine-based regimens are recommended for the treatment of toxoplasmosis. OBJECTIVE: The aim was to evaluate the safety profile of pyrimethamine-based treatment for the three main Toxoplasma manifestations: toxoplasmic encephalitis (TE), ocular toxoplasmosis, and congenital toxoplasmosis. METHODS: PubMed, Cochrane Library, and Google Scholar databases were searched through August 1, 2016. Randomized, observational, prospective/retrospective, and cohort studies were eligible. Thirty-one studies were included with a total of 2975 patients. Of these, 13 were in congenital toxoplasmosis (n = 929), 11 in ocular toxoplasmosis (n = 1284), and seven in TE (n = 687). Across manifestations, adverse event (AE)-related treatment discontinuation and/or change in therapy involved ≤37% of patients and occurred in >55% of studies: 100% for ocular toxoplasmosis, 57.1% for TE, and 61.5% for congenital toxoplasmosis. The most commonly observed AEs were bone marrow suppression, dermatologic, and gastrointestinal (GI). The prevalence of bone marrow suppression-related AEs was ≤50% in congenital toxoplasmosis, ≤42.7% in TE, and ≤9.0% in ocular toxoplasmosis. The frequency of GI and dermatologic AEs were ≤100 and ≤11.1%, respectively, for ocular toxoplasmosis, ≤10.7 and ≤17.9% for TE, and ≤10.8 and ≤2.1% for congenital toxoplasmosis. Steven-Johnson syndrome was reported in two patients with ocular toxoplasmosis and one with TE. CONCLUSION: The AE profile associated with pyrimethamine-based treatments differed by each manifestation of toxoplasmosis and within a given manifestation. Hematologic AEs occurred across all manifestations indicating the importance of monitoring the blood of patients administered pyrimethamine-based regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of encephalitis-associated hospitalizations in the United States, 1998-2010
Vora, N. M., Holman, R. C., Mehal, J. M., Steiner, C. A., Blanton, J., & Sejvar, J. (2014) · Neurology · doi:10.1212/wnl.0000000000000086 · Cited by 264
Cited by
Control of human toxoplasmosis
Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G. (2021) · International Journal for Parasitology · doi:10.1016/j.ijpara.2020.11.001 · Cited by 286
Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis
Elsheikha, H. M., Marra, C. M., & Zhu, X.-Q. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-19 · Cited by 262
Promising drug targets and compounds with anti-Toxoplasma gondii activity
Silva, M. D., Teixeira, C., Gomes, P., & Borges, M. (2021) · Microorganisms · doi:10.3390/microorganisms9091960 · Cited by 44
Kast, R. E. (2024) · Oncoscience · doi:10.18632/oncoscience.594 · Cited by 6
“Pyrimethamine treatment at higher doses can give a reversible bone marrow suppression, making periodic blood monitoring advisable [44, 45].”
Background
Metadata
- Authors
- Ben-Harari, R. R., Goodwin, E., & Casoy, J.
- Venue
- Drugs in R&D
- Published
- 2017-09-06
- Volume
- 17
- Issue
- 4
- Pages
- 523-544
- ISSN
- 1174-5886 (ISSN-L)
- 1179-6901
- OpenAlex
- W2753866799
- Cited by
- 180
- References
- 1
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review. https://app.cochat.ai/papers/10.1007/s40268-017-0206-8
- The paper
- Ben-Harari, R. R., Goodwin, E., & Casoy, J. (2017). Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review. Drugs in R&D. https://doi.org/10.1007/s40268-017-0206-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.